Faculty profile
Naveen Arya
Back to faculty41 publications.
Number, depth, and location of inadvertent pancreatic guidewire cannulations, and their association with post-ERCP pancreatitis: multicenter real-time intra-procedural data
Gupta M, Chau M, Howarth M, Cartwright S, Ficaccio S, Tepox-Padron A, Alshammari Y, Guo H, Chen Y-I, Singh A
Incidence, Risk Factors, and Outcomes of Post-endoscopic Retrograde Cholangiopancreatography Cholangitis: An International Multicenter Prospective Study
Gupta M, Fazal MA, Hammal J, Khan R, Forbes N, Group CW, Chen Y-I, Singh A, Hookey L, Bechara R
Multicenter Prospective Evidence of Kidney Safety of Nonsteroidal Anti-Inflammatory Drugs for Prevention of Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Howarth M, James M, Lam NN, Dixon E, Ruan Y, Forbes N, Group CW, Chen Y-I, Singh A, Hookey L
Patient-reported tolerability of endoscopic retrograde cholangiopancreatography using conscious sedation in patients with underlying depression and anxiety
Tepox-Padrón A, El-Gabalawy R, Cartwright S, Lee S, Gill P, Mishra P, Hammal J, Rivas A, Besney J, Samnani S
Correction: Number, depth, and location of inadvertent pancreatic guidewire cannulations, and their association with post-ERCP pancreatitis: multicenter real-time intra-procedural data
Gupta M, Chau M, Howarth M, Cartwright S, Ficaccio S, Tepox-Padron A, Alshammari Y, Guo H, Chen Y-I, Singh A
Practice patterns of endoscopic ultrasound-guided tissue acquisition of solid pancreatic masses: an international survey study
Tanner S, Marin R, Krishna SG, Espino A, Arya N, Chen Y-I, Dhir V, Facciorusso A, Forbes N, Sahai AV
Endoscopic retrograde cholangiopancreatography-related adverse events and unplanned hospital encounters in patients with underlying depression and anxiety
Tepox-Padrón A, El-Gabalawy R, Hilsden RJ, Cartwright S, Lee S, Gill P, Mishra P, Hammal J, Rivas A, Besney J
Adverse events, success, and tolerability of biliary endoscopic retrograde cholangiopancreatography with conscious sedation vs anaesthesia: a multi-centre prospective study
Smith ZL, Kayal A, Ruan Y, Lethebe BC, Siersema PD, Padrón AT, Alshammari Y, Samnani S, Koury HF, Chau M
DOP050 Target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial
Jairath V, Zou G, Adsul S, Colombel JF, D'Haens GR, Freire M, Moran GW, Sebastian S, Travis S, Vermeire S
DOP007 Change in Histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial
Jairath V, Peyrin-Biroulet L, Magro F, Zou G, Adsul S, Colombel JF, D’Haens GR, Freire M, Moran GW, Sebastian S
Frequent collaborators
3A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.